Biogen Idec Inc. 10-Q Summary: Quarter Ended September 30, 2007
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Biogen Idec Inc. for the period ended September 30, 2007. Biogen Idec is an international biotechnology company focused on oncology, neurology, and immunology. The company's portfolio includes AVONEX, RITUXAN, TYSABRI, FUMADERM, and ZEVALIN. The reporting period reflects significant strategic shifts, including a major share repurchase tender offer, new collaboration agreements, and the planned divestiture of the ZEVALIN U.S. business.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Total Revenues | $789.2 million | $2,278.3 million | $1,974.7 million |
| Net Income | $119.4 million | $437.0 million | $109.0 million |
| Diluted EPS | $0.41 | $1.34 | $0.31 |
| Operating Cash Flow (9mo) | $674.8 million | ||
| Cash & Cash Equivalents (Sep 30, 2007) | $437.3 million | ||
| Total Debt (Sep 30, 2007) | $1,560.2 million | ||
| Working Capital (Sep 30, 2007) | $(368.3) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 12.2% year-over-year for the nine months ended September 30, 2007, driven primarily by the re-launch of TYSABRI and price increases on AVONEX.
- Profitability: Net income for the nine months increased significantly to $437.0 million from $109.0 million in the prior year. This improvement was aided by a lower effective tax rate (29.0% vs. 66.2% in 2006) and the absence of large non-deductible in-process research and development (IPR&D) charges that impacted the prior year.
- Debt Structure: The company incurred substantial new debt to fund a tender offer. As of September 30, 2007, total borrowings were $1,560.2 million, compared to $96.7 million at year-end 2006. This includes a $1.5 billion term loan facility.
- Working Capital: Working capital turned negative to $(368.3) million from a positive $1,129.7 million at December 31, 2006, primarily due to the cash outflow for the tender offer.
Guidance, Outlook, and Management Commentary
- Share Repurchase: In July 2007, the company completed a tender offer repurchasing 56.4 million shares for approximately $2.99 billion. This was funded by existing cash and the new $1.5 billion term loan.
- Strategic Transactions:
- ZEVALIN Divestiture: Agreed to sell U.S. rights to ZEVALIN to Cell Therapeutics Inc. for $10 million upfront plus milestones and royalties. Expected to close in Q4 2007.
- Cardiokine Collaboration: Entered an agreement for the joint development of lixivaptan, paying a $50 million upfront fee (expensed as R&D) with potential milestones up to $170 million.
- Syntonix Acquisition: Completed acquisition of Syntonix Pharmaceuticals for $44.4 million to expand the hemophilia pipeline.
- Acquisition Evaluation: On October 12, 2007, the Board authorized management to evaluate potential third-party acquisitions of the Company to determine if a transaction would offer better value than the stand-alone strategy.
- Outlook: Management anticipates R&D and SG&A expenses to remain higher in 2007 compared to 2006 due to clinical trial activity and support for TYSABRI and AVONEX growth.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the financial covenants of the new $1.5 billion term loan and $400 million revolving credit facility, specifically the maximum leverage ratio.
- TYSABRI Performance: Monitor TYSABRI sales growth and market acceptance, as near-term success is heavily dependent on this product following its re-launch.
- Acquisition Process: Track the status of the Board's evaluation of a potential acquisition of Biogen Idec, which could lead to a change of control.
- Legal Proceedings: Review ongoing litigation, including the class action lawsuit regarding TYSABRI safety disclosures and the arbitration with Genentech regarding the collaboration agreement.
- Manufacturing Capacity: Assess the progress and cost of the Hillerod, Denmark manufacturing facility expansion, which is critical for meeting future TYSABRI demand.